VIRI - Virios Therapeutics soars 17% on promising IMC-1 data in Phase 2a fibromyalgia trial

Virios Therapeutics (VIRI) jumps 17% premarket in reaction to the data from its Phase 2a clinical trial PRID-201 evaluating IMC-1 in patients with fibromyalgia ((FM)). IMC?1 exhibited an encouraging safety profile, as AEs occurred at a lower rate and were less severe in the IMC?1 treatment group compared with placebo.The discontinuation rate was nearly 3?fold higher in patients receiving placebo compared to IMC?1 group, suggesting that treatment with IMC?1 was unusually well?tolerated.Significant reductions in pain, fatigue, and other important symptoms were seen and results suggest that IMC?1 may offer a promising and well?tolerated option to treat FM.The data were presented at the IASP World Congress, held virtually June 9 - 11, and June 16 - 18, 2021

For further details see:

Virios Therapeutics soars 17% on promising IMC-1 data in Phase 2a fibromyalgia trial